From the Departments of Rheumatology and Clinical Epidemiology, Leiden University Medical Center, Leiden, the Netherlands; Paris 6, Sorbonne Universités, GRC-08 (EEMOIS); AP-HP, Department of Rheumatology, Pitié Salpêtrière University Hospital, Paris, France; Spire Sciences Inc., Boca Raton, Florida; Data and Statistical Sciences, and Immunology Development, AbbVie Inc., North Chicago, Illinois; Departments of Radiology and Medicine, University of California at San Francisco, San Francisco, California; AbbVie Inc., Cambridge, Massachusetts, USA; Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and National Institute for Health Research, Leeds Biomedical Research Centre, Leeds, UK; Department of Diagnostic Imaging, Sheba Medical Center, Tel Aviv University, Tel Aviv, Israel; Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway; Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup; Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.
F.P. Kroon, MD, Department of Rheumatology, Leiden University Medical Center; S. van Beest, MD, Department of Rheumatology, Leiden University Medical Center; F. Gandjbakhch, MD, Practicing Rheumatologist, Paris 6, Sorbonne Universités, GRC-08 (EEMOIS), and AP-HP, Department of Rheumatology, Pitié Salpêtrière University Hospital; C.G. Peterfy, MD, PhD, FRCP, Chief Executive Officer, Spire Sciences Inc.; S. Chen, Data and Statistical Sciences, AbbVie Inc.; P.G. Conaghan, MB, BS, PhD, FRACP, FRCP, Professor of Musculoskeletal Medicine, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and National Institute for Health Research, Leeds Biomedical Research Centre; I. Eshed, MD, Associate Professor of Radiology, Department of Diagnostic Imaging, Sheba Medical Center, Tel Aviv University; V. Foltz, MD, Practicing Rheumatologist, Paris 6, Sorbonne Universités, GRC-08 (EEMOIS), and AP-HP, Department of Rheumatology, Pitié Salpêtrière University Hospital; H.K. Genant, MD, FACR, FRCR, Professor Emeritus of Radiology, Medicine and Orthopedics, Departments of Radiology and Medicine, University of California at San Francisco; I.K. Haugen, MD, PhD, Postdoctoral Researcher, Department of Rheumatology, Diakonhjemmet Hospital; J.K. Medema, MS, Senior Project Leader, Immunology Development, AbbVie Inc.; M. Østergaard, MD, PhD, DMSc, Professor of Rheumatology, Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup, Denmark, and Department of Clinical Medicine, University of Copenhagen; L. Zhang, Data and Statistical Sciences, AbbVie Inc.; M.C. Levesque, MD, PhD, Foundational Immunology Senior Director, AbbVie Inc.; M. Kloppenburg, MD, PhD, Professor of Rheumatology, Departments of Rheumatology and Clinical Epidemiology, Leiden University Medical Center.
J Rheumatol. 2019 Sep;46(9):1228-1231. doi: 10.3899/jrheum.180949. Epub 2018 Dec 15.
To assess the longitudinal reliability of the Outcome Measures in Rheumatology (OMERACT) Thumb base Osteoarthritis Magnetic resonance imaging (MRI) Scoring system (TOMS).
Paired MRI of patients with hand osteoarthritis were scored in 2 exercises (6-mo and 2-yr followup) for synovitis, subchondral bone defects (SBD), osteophytes, cartilage assessment, bone marrow lesions (BML), and subluxation. Interreader reliability of delta scores was assessed.
Little change occurred. Average-measure intraclass correlation coefficients were good-excellent (≥ 0.71), except synovitis (0.55-0.83) and carpometacarpal-1 osteophytes/cartilage assessment (0.47/0.39). Percentage exact/close agreement was 52-92%/68-100%, except BML in 2 years (28%/64-76%). Smallest detectable change was below the scoring increment, except in SBD and BML.
TOMS longitudinal reliability was moderate-good. Limited change hampered assessment.
评估关节炎疗效评价方法(OMERACT)拇指基底关节炎磁共振成像(MRI)评分系统(TOMS)的纵向可靠性。
对患有手部骨关节炎的患者进行两次 MRI 扫描(6 个月和 2 年随访),评估滑膜炎、软骨下骨缺损(SBD)、骨赘、软骨评估、骨髓病变(BML)和半脱位情况。评估 delta 评分的读者间可靠性。
变化不大。平均测量的组内相关系数为良好至优秀(≥0.71),除滑膜炎(0.55-0.83)和掌指关节 1 骨赘/软骨评估(0.47/0.39)外。确切/接近一致的百分比为 52-92%/68-100%,除了 2 年内的 BML(28%/64-76%)。除 SBD 和 BML 外,最小可检测变化低于评分增量。
TOMS 纵向可靠性为中等至良好。有限的变化阻碍了评估。